{"classes":[{"categories":[{"measurements":[{"comment":"The median and upper limit of 95% CI is NR (not reached). The median and upper limit were not reached because there was not enough follow up time to reach a median or upper limit.","groupId":"OG000","lowerLimit":"16.2","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"PFS is defined as the time from study entry until progression or death. Progression is assessed by the International Myeloma Workshop Consensus Panel Criteria. Progressive disease requires any one or more of the following: increase of ≥25% from baseline or lowest response value in Serum M component, Urine M component, free light chain or bone marrow plasma cell percentage. Lowest response value does not need to be a confirmed value. Serum M-component absolute increase must be ≥0.5 g/dl. The serum M-component increases of ≥1 gm/dl are sufficient to define relapse if starting M-component is ≥5 g/dl. Urine M-component absolute increase must be ≥200mg/24h. Only in patients without measureable serum and urine M-protein levels: the absolute increase in difference between involved and uninvolved free light chain levels must be \\>10mg/dl.","dispersionType":"95% Confidence Interval","groups":[{"description":"10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.\n\nLenalidomide: 10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.","id":"OG000","title":"Lenalidomide Maintenance Therapy for Multiple Myeloma"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"participants were followed for the duration of their treatment, an average of 2 years","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}